SARS-CoV-2 and COVID-19 Research

This study analyzes SARS-CoV-2 ORF8 sequence conservation and mutations across variants to assess how dataset size affects identification of top mutations.

This study compares SARS-CoV-2 immune responses in head and neck cancer patients and controls, finding similar antibody levels but higher convalescent/hybrid immunity and stable B-cell responses.

This paper designs SARS-CoV-2 RBD immunogens that shift immune responses towards conserved epitopes, improving cross-reactivity against variants.

This paper shows that MK-8722, a direct AMPK activator, inhibits SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy, and enhancing type I IFN response, even when applied post-exposure.

The paper develops a SARS-CoV-2-derived viral vector system for antiviral drug screening and research, showing it can infect human cells and is sensitive to remdesivir and interferons.

Non-stabilized SARS-CoV-2 Spike mRNA vaccination in macaques induces B cell lineages targeting conserved epitopes on Omicron variants or cross-neutralizing epitopes on Sarbecoviruses.

The paper develops a SARS-CoV-2 vaccine in mink and evaluates its immune response and efficacy against Alpha and Omicron variants, showing reduced severity and virus presence in vaccinated animals.

This study shows that the furin cleavage site (FCS) is essential for SARS-CoV-2 pathogenesis but not for transmission, as a mutant lacking FCS was transmissible in hamsters but caused less severe disease.

This study uses single-molecule techniques to show that SARS-CoV-2 spike protein RBD dynamics modulate ACE2 binding through conformational selection without affecting unbinding.

The paper calculates nonequilibrium binding energy (NEBE) for SARS-CoV-2 variants under different conditions and finds that NEBE decreases with increasing temperature, suggesting potential implications for drug administration.

This paper predicts SARS-CoV-2 RBD evolution using deep mutational scanning to identify broadly neutralizing antibodies effective against existing and prospective variants.

This paper introduces a Variant Evolution Graph (VEG) to model SARS-CoV-2 variant evolution using mutational distances and genotypes from GISAID, and infers disease transmission networks.

This paper introduces a few-shot learning framework for detecting high-fitness viral variants using Bayesian active learning and biophysics, showing it can identify variants up to fivefold faster with fewer experiments.

This study analyzes how different antibodies interact with SARS-CoV-2 spike protein using computational methods to identify binding hotspots and resistance mechanisms against variants.

SARS-CoV-2 variant BA.3.2 strongly evades neutralizing antibodies but exhibits low infectivity due to a closed spike conformation, whereas NB.1.8.1 combines high ACE2 affinity with humoral immune escape.

The paper designs a protein that binds to multiple SARS-CoV-2 RBD variants with high affinity, demonstrating a strategy for broad-spectrum antiviral inhibitors.

This study shows that immunity from previous infection or vaccination does not always prevent brain infection by antigenically distinct SARS-CoV-2 variants in animal models.

This study shows Amphotericin B and Nystatin enhance SARS-CoV-2 replication in vitro by promoting viral entry, suggesting they should not be used in active COVID-19 cases.

This study uses cryo-ET to capture complete SARS-CoV-2 fusion intermediates, revealing structural changes and the inhibitory effect of the WS6 S2 antibody.

This study shows that cigarette smoke increases ACE-2 and TMPRSS2 expression in airway cells, enhancing SARS-CoV-2 infection, which is mitigated by ACE-2 blockade and TMPRSS2 inhibition.

This study designs miniproteins that inhibit MERS-CoV by targeting the spike protein, showing broad neutralization and protective efficacy in mice.

This study evaluates monoclonal antibody responses to XBB.1.5 vaccines by analyzing plasmablasts from vaccinated individuals and characterizing their binding and neutralization properties against SARS-CoV-2 variants.

This study evaluates two nasal coronavirus vaccines in African Green Monkeys, showing they induce cross-reactive immunity and neutralizing responses against SARS-CoV-2 and related coronaviruses.

The paper identifies ACE2 as a receptor for HKU5 coronaviruses from Pipistrellus abramus bats and investigates receptor tropism across merbecovirus clades.

This study reveals how the SARS-CoV-2 N-protein's interdomain linker drives dynamic self-assembly and phase separation through coiled-coil interactions.

This study identifies pyrrolo-pyrimidine-based Mac1 inhibitors that inhibit MHV and SARS-CoV-2 replication, with some compounds showing IFN-dependent antiviral activity.

This paper develops mosaic RBD-nanoparticles to induce cross-reactive anti-sarbecovirus antibodies in animals, demonstrating their effectiveness against SARS-CoV-2 variants and zoonotic viruses.

This study uses high-throughput screens in human cells with authentic SARS-CoV-2 virus to identify neutralizing monoclonal antibodies and kinase inhibitors with minimal host toxicity.

The paper derives equations to quantify thermodynamic parameters of SARS-CoV-2 infection, highlighting the dual role of viscosity and cholesterol in pathophysiology.